SARASOTA, FL and LEVERKUSEN, GERMANY -- (MARKET WIRE) -- December 27, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that its German business partner, Biofrontera AG (FRANKFURT: B8F), in which the Company owns an approximate 10% stake, has completed the enrollment of patients in the first part of its phase IIb/III clinical trial for its lead product, BF-200 ALA, a proposed treatment of actinic keratosis (precancerous and cancerous skin lesions).
